Suppr超能文献

作为潜在临床绩效指标的抗高血压药物依从性与治疗强化之间的比较。

A comparison between antihypertensive medication adherence and treatment intensification as potential clinical performance measures.

作者信息

Vigen Rebecca, Shetterly Susan, Magid David J, O'Connor Patrick J, Margolis Karen L, Schmittdiel Julie, Ho P Michael

机构信息

University of Colorado, Denver, CO 80220, USA.

出版信息

Circ Cardiovasc Qual Outcomes. 2012 May;5(3):276-82. doi: 10.1161/CIRCOUTCOMES.112.965665. Epub 2012 May 10.

Abstract

BACKGROUND

Medication adherence and treatment intensification have been advocated as performance measures to assess the quality of care provided. Whereas previous studies have shown that adherence and treatment intensification (TI) of antihypertensive medications is associated with blood pressure (BP) control at the patient level, less is known about whether adherence and TI is associated with BP control at the clinic level.

METHODS AND RESULTS

We included 162 879 patients among 89 clinics in the Cardiovascular Research Network Hypertension Registry with incident hypertension who were started on antihypertensive medications. Adherence was measured by the proportion of days covered (PDC). TI was defined by the standard based method with scores ranging between -1 to 1 and categorized as: -1 indicated no TI occurred when BP was elevated; 0 indicated TI occurred when BP was elevated; and 1 indicated that TI was made at all visits, even when BP was not elevated. Logistic regression models assessed the association between adherence and TI with blood pressure control (BP ≤ 140/90 at the clinic visit closest to 12 months after study entry) at the patient and clinic levels. Mean adherence was 0.77 ± 0.28 (PDC ± SD) at the patient level and 0.78 ± 0.05 at the clinic level. Mean TI was 0.026 ± 0.23 at the patient level and 0.01 ± 0.04 at the clinic level. At the patient level, for each 0.25 increase in adherence and TI, the odds (OR) of achieving blood pressure control increased by 28% and 55%, respectively [OR for adherence, 1.28 (1.26-1.29), and for TI, 1.55 (1.53-1.57)]. At the clinic level, each 0.04 increment increase in treatment intensification was associated with a 25% increased odds of achieving blood pressure control (OR, 1.24; 95% CI, 1.21-1.27). In contrast, there was an inverse association between increasing adherence and BP control (OR, 0.93; 95% confidence interval, 0.90-0.95).

CONCLUSIONS

Patient adherence to antihypertensive medications is not associated with BP control at the clinic level and may not be suitable as a performance measure. TI is associated with BP control, but its use as a performance measure may be constrained by challenges in measuring it and by concerns about unintended consequences of aggressive hypertension treatment in some subgroups of patients.

摘要

背景

药物依从性和治疗强化已被倡导作为评估所提供医疗质量的绩效指标。尽管先前的研究表明,降压药物的依从性和治疗强化在患者层面与血压(BP)控制相关,但对于依从性和治疗强化在诊所层面是否与血压控制相关,人们了解较少。

方法与结果

我们纳入了心血管研究网络高血压登记处89家诊所中的162879例初发高血压且开始服用降压药物的患者。依从性通过覆盖天数比例(PDC)来衡量。治疗强化采用基于标准的方法定义,分数范围在 -1至1之间,并分类如下:-1表示血压升高时未进行治疗强化;0表示血压升高时进行了治疗强化;1表示在所有就诊时均进行了治疗强化,即使血压未升高。逻辑回归模型评估了患者和诊所层面的依从性和治疗强化与血压控制(在研究入组后最接近12个月的诊所就诊时血压≤140/90)之间的关联。患者层面的平均依从性为0.77±0.28(PDC±标准差),诊所层面为0.78±0.05。患者层面的平均治疗强化值为0.026±0.23,诊所层面为0.01±0.04。在患者层面,依从性和治疗强化每增加0.25,实现血压控制的几率(OR)分别增加28%和55%[依从性的OR为1.28(1.26 - 1.29),治疗强化的OR为1.55(1.53 - 1.57)]。在诊所层面,治疗强化每增加0.04,实现血压控制的几率增加25%(OR,1.24;95%CI,1.21 - 1.27)。相比之下,依从性增加与血压控制呈负相关(OR,0.93;95%置信区间,0.90 - 0.95)。

结论

患者对降压药物的依从性在诊所层面与血压控制无关,可能不适宜作为绩效指标。治疗强化与血压控制相关,但其作为绩效指标的应用可能受到测量方面的挑战以及对某些患者亚组积极高血压治疗意外后果的担忧的限制。

文献检索

告别复杂PubMed语法,用中文像聊天一样搜索,搜遍4000万医学文献。AI智能推荐,让科研检索更轻松。

立即免费搜索

文件翻译

保留排版,准确专业,支持PDF/Word/PPT等文件格式,支持 12+语言互译。

免费翻译文档

深度研究

AI帮你快速写综述,25分钟生成高质量综述,智能提取关键信息,辅助科研写作。

立即免费体验